Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin. (NSTE-ACS)

Inclusion Criteria:

• Hospitalised for chest pain and potential acute coronary syndrome.
• Onset of the most recent cardiac ischemic symptoms must occur within 7 days before randomisation and documented by cardiac ischemic symptoms of ≥ 10 min duration at rest and at least 2 of the following: ST segment changes on electrocardiogram (ECG) indicative of ischemia, or Positive biomarker evdience of myocardial necrosis, or other risk factors such as: 60 yrs of age or older, previous myocardial infarction or coronary bypass surgery, multi-vessel coronary artery disease, diabetes mellitus, peripheral arterial disease, chronic renal disfunction.
• Females must be either surgically sterile or post-menopausal.
• Activated Clotting Time (ACT) </= 300 at the time of study treatment

Exclusion Criteria:

• Participation in another clinical study with an investigational product during the last 30 days.
• Current acute complication of percutaneous coronary intervention or coronary bypass surgery.
• Any contraindication to ticagrelor, clopidogrel or bivalirudin.
• ST elevation myocardial infraction within 24 hours of study entry.
• Any indications for oral anticoagulation or aspirin dose other than 75 to 100 milligrams (mg) daily.
• Planned use of omeprazole or esomeprazole.
• Patients with known bleeding or coagulation disorders; patients requiring dialysis; patients who have an inability to swallow medication.
• Patients with known bleeding diathesis or coagulation disorder; history of intracranial bleed.
• Use of Intravenous (IV) heparin less than 2 hours before procedure.
• Sustained uncontrolled high blood pressure